Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.

Agomab Therapeutics Acquires Origo Biopharma

December 15, 2021

Biotechnology

Agomab Therapeutics NV has completed the acquisition of Spanish biotech Origo Biopharma, integrating Origo's team and facilities in Touro and Barcelona into Agomab's organization. The deal combines Origo's organ‑restricted small‑molecule platform targeting the TGF‑β pathway with Agomab's HGF‑targeting antibody programs to broaden the combined clinical‑stage pipeline for fibrosis therapeutics.

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Takeda to Acquire Adaptate Biotherapeutics to Expand γδ T Cell Engager Platform for Solid Tumors

January 10, 2022

Biotechnology

Takeda Pharmaceutical Company has exercised its option to acquire Adaptate Biotherapeutics, a UK immunotherapy company developing antibody-based therapeutics that modulate Vδ1 gamma delta (γδ) T cells. The acquisition will add Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidates and discovery pipeline programs, to Takeda’s immuno-oncology portfolio.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.